↓ Skip to main content

Stem cell transplantation for rheumatic autoimmune diseases

Overview of attention for article published in Arthritis Research & Therapy, January 2008
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

blogs
1 blog

Readers on

mendeley
59 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Stem cell transplantation for rheumatic autoimmune diseases
Published in
Arthritis Research & Therapy, January 2008
DOI 10.1186/ar2486
Pubmed ID
Authors

Thomas Hügle, Jacob M van Laar

Abstract

Immunoablative therapy and hematopoietic stem cell transplantation (HSCT) is an intensive treatment modality aimed at 'resetting' the dysregulated immune system of a patient with immunoablative therapy and allow outgrowth of a nonautogressive immune system from reinfused hematopoietic stem cells, either from the patient (autologous HSCT) or a healthy donor (allogeneic HSCT). HSCT has been shown to induce profound alterations of the immune system affecting B and T cells, monocytes, and natural killer and dendritic cells, resulting in elimination of autoantibody-producing plasma cells and in induction of regulatory T cells. Most of the available data have been collected through retrospective cohort analyses of autologous HSCT, case series, and translational studies in patients with refractory autoimmune diseases. Long-term and marked improvements of disease activity have been observed, notably in systemic sclerosis, systemic lupus erythematosus, and juvenile idiopathic arthritis, and treatment-related morbidity and mortality have improved due to better patient selection and modifications of transplant regimens. Treatment-related mortality has decreased to approximately 7%. Prospective, randomised, controlled clinical trials are ongoing or planned in systemic sclerosis, systemic lupus erythematosus, and several nonrheumatological conditions.

Mendeley readers

The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Philippines 1 2%
Sweden 1 2%
Canada 1 2%
Unknown 55 93%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 20%
Student > Master 12 20%
Researcher 9 15%
Student > Bachelor 8 14%
Other 5 8%
Other 12 20%
Unknown 1 2%
Readers by discipline Count As %
Medicine and Dentistry 33 56%
Agricultural and Biological Sciences 8 14%
Biochemistry, Genetics and Molecular Biology 4 7%
Immunology and Microbiology 3 5%
Psychology 2 3%
Other 6 10%
Unknown 3 5%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2008.
All research outputs
#2,617,526
of 14,091,587 outputs
Outputs from Arthritis Research & Therapy
#769
of 2,274 outputs
Outputs of similar age
#2,506,390
of 13,347,038 outputs
Outputs of similar age from Arthritis Research & Therapy
#769
of 2,273 outputs
Altmetric has tracked 14,091,587 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,274 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 13,347,038 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 2,273 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.